NMRA
Neumora Therapeutics, Inc. Common Stock
There isn't enough reported data to score NMRA yet.
NMRA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
NMRA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
NMRA PE Valuation
NMRA has no meaningful PE right now: it lost money over the past year.
NMRA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect NMRA's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
NMRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.23 | +$0.34 |
| Q1 2026 | -$1.33 | +$0.28 |
| Q4 2025 | -$1.45 | +$0.08 |
| Q3 2023 | -$1.81 | -$0.96 |
| Q2 2023 | -$0.86 | +$0.97 |
| Q1 2023 | -$0.81 | +$0.93 |
| Q4 2022 | -$0.86 | +$0.70 |
| Q3 2022 | -$0.85 | +$0.66 |
NMRA is still losing money, but less than at its worst: $1.23 per share over the past year, against $1.83 at its worst in mid-2022.
NMRA Quarterly Revenue
NMRA's revenue is shrinking: $0 last quarter.
NMRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$39.5M | +$12.9M |
| Q1 2026 | -$46.4M | +$13M |
| Q4 2023 | -$51.5M | -$21.1M |
| Q2 2023 | -$31M | -$4.3M |
| Q1 2023 | -$33.1M | -$715K |
| Q4 2022 | -$30.4M | -$849K |
| Q3 2022 | -$25.9M | -$8.4M |
| Q2 2022 | -$26.8M | -$13.1M |
NMRA has burned cash in almost every quarter: −$186M over the past year, against −$175M the year before.
NMRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.9% | +5.3M shares |
| 1 year | +15% | +23.5M shares |
| 3 years | +22% | +33.2M shares |
| 5 years | +22% | +33.2M shares |
NMRA has 185M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
NMRA Net Leverage
NMRA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NMRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.6 | Oversold |
| Stochastic | 8.1 | Oversold |
NMRA's weekly RSI is 28 (oversold) and its Stochastic is 8 (oversold).
NMRA PE vs Healthcare Sector
NMRA has no meaningful PE right now: it lost money over the past year.
NMRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.48 | 10% below |
| 20 week MA | $1.06 | 59% below |
| 50 week MA | $1.74 | 75% below |
| 100 week MA | $1.83 | 77% below |
NMRA is in a downtrend: it's below all four of its weekly moving averages, and 77% below its 100-week average.
NMRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $16.3 | $17.1 | +4.9% |
| 2024 | $17.1 | $11.3 | -34% |
| 2025 | $11.3 | $1.78 | -84% |
| 2026 YTD | $1.78 | $0.43 | -76% |
NMRA has finished lower in two of the last three years. It's down 76% so far in 2026.